A carregar...
TRK inhibitors in TRK fusion-positive cancers
TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-generation TRK inhibitors, larotrectinib and entrectinib, were granted landmark, tumour-agnostic regulatory approvals for the treatment of these cancers in 2018 and 2019, respectively. Brisk and durable responses ar...
Na minha lista:
| Publicado no: | Ann Oncol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6859818/ https://ncbi.nlm.nih.gov/pubmed/31738426 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz282 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|